CHRS Q1 2022 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M-27.6% YoY

Gross Profit

$51M84.4% margin

Operating Income

-$81M-134.6% margin

Net Income

-$96M-159.8% margin

EPS (Diluted)

$-1.44

QoQ Revenue Growth

-18.1%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$593M

Total Liabilities

$581M

Stockholders' Equity

$13M

Cash & Equivalents

$326M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$83M	-27.6%
Gross Profit	$51M	$76M	-32.8%
Operating Income	-$81M	-$167M	+51.6%
Net Income	-$96M	-$173M	+44.4%

Revenue Segments

Product Revenue

$60M100%